FDA approves Afrezza for pediatric diabetes patients

Dansk

The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.

MannKind Corporation announced the approval during a call led by CEO Michael Castagna. He described the day as a historic moment for the company, the diabetes community, and young patients. Castagna noted that founder Al Mann had long envisioned the treatment reaching children, and the company is fulfilling that goal.

Relaterede artikler

Illustration showing long COVID patients revitalized by fluvoxamine treatment in a clinical trial, with scientists and physician highlighting study results.
Billede genereret af AI

Fluvoxamin lindrer svær træthed hos long-covid-patienter

Rapporteret af AI Billede genereret af AI

Et studie viser, at antidepressivet fluvoxamin reducerer svær træthed hos long-covid-patienter. I et randomiseret forsøg med 399 voksne blev det sammenlignet med metformin og placebo. Overlæge Judith Bruchfeld betegner resultaterne som interessante.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Rapporteret af AI

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Teknologi

Dexcom outlines growth plans at 2026 investor day

Sundhed

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Sundhed

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Rapporteret af AI

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

søndag d. 14. juni 2026, 20.53

France reimburses Mounjaro and Wegovy for severe obesity

onsdag d. 10. juni 2026, 04.55

Novo Nordisk heads to South African court over semaglutide copies

torsdag d. 28. maj 2026, 07.51

Three million kronor for research on mast cells in asthma

torsdag d. 14. maj 2026, 00.38

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

tirsdag d. 12. maj 2026, 00.48

Semaglutide shows strong weight loss results for adults over 65

torsdag d. 7. maj 2026, 17.40

Swedish team restores blood sugar control in diabetic mice

onsdag d. 6. maj 2026, 06.50

Innovative Cape Town clinic boosts outcomes for young kidney patients

torsdag d. 16. april 2026, 15.29

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

mandag d. 13. april 2026, 22.13

FDA approves Travere Therapeutics' FILSPARI for FSGS

mandag d. 23. marts 2026, 12.25

Studie anbefaler behandling til alle børn med svær overvægt

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis